Oncology
Agendia Appoints Suja Chandrasekaran and Scott Mendel to Board of Directors, Strengthening Advisory Group to Support Company Momentum
06/01/2022 — IRVINE, Calif. & AMSTERDAM — (BUSINESS WIRE) Agendia, Inc., a commercial stage company focused on precision oncology for breast cancer, today announced the appointment of healthcare industry veterans […]
Personalis Launches NeXT Personal™, A Tumor-Informed Liquid Biopsy Assay for MRD and Recurrence Detection With Part-Per-Million Sensitivity
16/12/2021 — MENLO PARK, Calif. — (BUSINESS WIRE) Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of NeXT Personal, a next-generation, tumor-informed liquid […]
Agendia Spotlight Poster at SABCS 2021 Confirms Utility of BluePrint® as Biomarker Subtyping Test to Guide Neoadjuvant Chemotherapy Decisions
Additional research from the real-world FLEX Registry focuses on age effect and lymph node status for patients with breast cancer 10/12/2021 — IRVINE, Calif. & AMSTERDAM — (BUSINESS WIRE) Agendia, […]
Analysis Presented at SABCS 2021 Confirms MammaPrint® and BluePrint® Predict Outcomes Following Neoadjuvant Chemotherapy
Data signal importance of serial genomic testing in order to appropriately adjust breast cancer treatment plans 09/12/2021 — IRVINE, Calif. & AMSTERDAM — (BUSINESS WIRE) Agendia, Inc., a world leader […]
LintonPharm Announces First Patient Dosed in Phase 1 Clinical Trial of Catumaxomab for Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin
01/12/2021 — GUANGZHOU, China — (BUSINESS WIRE) LintonPharm Co., Ltd., a China-based clinical stage biopharmaceutical company focused on the development of T cell engaging bispecific antibodies for cancer immunotherapy, today […]
Personalis Announces Updates to NeXT Platform™ Incorporating Additional Key Profiling Capabilities for Advancing Oncology Biomarkers
02/11/2021 — MENLO PARK, Calif. — (BUSINESS WIRE) Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the latest expansion of the Personalis NeXT Platform® adding […]
Kyowa Kirin International: New Real World Evidence Underlines Benefits of POTELIGEO®▼ (mogamulizumab) Treatment for Cutaneous T-cell Lymphoma (CTCL) Patients
Patients responded better to treatment with POTELIGEO in real life, compared to data from the pivotal Phase 3 MAVORIC trial1 14/10/2021 — GALASHIELS, Scotland — (BUSINESS WIRE) Kyowa Kirin International […]
Ultivue Announces New Independent Board Members
19/08/2021 — CAMBRIDGE, Mass. — (BUSINESS WIRE) Ultivue announces the addition of two independent board members, Fenel Eloi and Mary Pat Lancelotta, to help strengthen its position as a leader […]
Personalis, Inc. Publishes New Data Demonstrating a Novel Composite Biomarker NEOPS™ for Predicting Response to Cancer Immunotherapy in Late-Stage Melanoma Patients
02/08/2021 — MENLO PARK, Calif. — (BUSINESS WIRE) Personalis, Inc. (Nasdaq: PSNL), a leader in advanced translational genomics and diagnostics for cancer, today announced the publication of its study “Prediction […]
McKesson Corporation Enters Agreement to Sell Certain European Businesses to the PHOENIX Group
Transaction enhances McKesson’s focus and commitment to future investments in strategic growth, including oncology and biopharma services, and core pharmaceutical and medical distribution Agreement includes the sale of McKesson Europe […]
Personalis Announces NeXT Level Biomarkers Symposium
22/06/2021 — MENLO PARK, Calif. — (BUSINESS WIRE) Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced its inaugural event, NeXT Level Biomarkers Symposium, which will […]
Personalis, Inc. to Present at Biomarkers Week Online 2021
17/05/2021 — MENLO PARK, Calif. — (BUSINESS WIRE) Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will present at Biomarkers Week Online […]
Ultivue Announces $50M Financing Round
27/04/2021 — CAMBRIDGE, Mass. — (BUSINESS WIRE) Ultivue, a leader in advancing precision medicine solutions through a unique approach that combines multiplex biomarker analysis with same slide traditional H&E for […]
LintonPharm Announces Authorization from China Health Authority (NMPA) to Proceed with a Phase 1/2 Trial Evaluating Catumaxomab for the treatment of Non-Muscle Invasive Bladder Cancer
13/04/2021 — GUANGZHOU, China — (BUSINESS WIRE) LintonPharm Co., Ltd., a China-based clinical stage biopharmaceutical company focused on the development of T cell engaging bispecific antibodies for cancer immunotherapy, today […]
Natera and Personalis Partner for Personalized Monitoring in Oncology
17/02/2021 — MENLO PARK, Calif. & SAN CARLOS, Calif. — (BUSINESS WIRE) Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, and Natera, Inc. (Nasdaq: NTRA), a global […]
European Commission Approves Seagen’s TUKYSA® (tucatinib) for the Treatment of Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer
– Approved for Adult Patients with HER2-Positive Metastatic Breast Cancer Who Have Received at Least Two Prior Anti-HER2 Treatment Regimens – – First HER-2 Tyrosine Kinase Inhibitor Combination Regimen to […]
Quotient Sciences Acquires Arcinova, the UK-Based Contract Development and Manufacturing Organization
09/02/2021 — NOTTINGHAM, England — (BUSINESS WIRE) Quotient Sciences, the drug development and manufacturing accelerator, announced that it has acquired Arcinova, the U.K.-based multiservice contract development and manufacturing organization (CDMO). […]
Atomwise and FutuRx Launch A2i Therapeutics – A New Immuno-Oncology Company Funded By Leading Biopharma VCs and the Israeli Innovation Authority
A2i Therapeutics secures seed funding from FutuRx and its investors – Johnson & Johnson Innovation (JJDC, Inc.), Takeda Ventures, OrbiMed Partners, Leaps by Bayer and the Israeli Innovation Authority – […]
Personalis Announces the Launch of NEOPS™, a Neoantigen-based Composite Biomarker for Cancer Immunotherapy Response
17/12/2020 — MENLO PARK, Calif. — (BUSINESS WIRE) Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of its proprietary Neoantigen Presentation Score (NEOPS). […]
Personalis Announces the Launch of SHERPA™ for High-Accuracy Neoantigen Prediction and Cancer Diagnostic Biomarker Development
17/12/2020 — MENLO PARK, Calif. — (BUSINESS WIRE) Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of its Systematic HLA Epitope Ranking Pan […]
Trastuzumab Deruxtecan Recommended for Approval in the EU by CHMP for HER2 Positive Metastatic Breast Cancer
Recommendation based on positive results from the DESTINY-Breast01 trial, which showed durable responses in patients with previously treated disease 11/12/2020 — TOKYO & MUNICH — (BUSINESS WIRE) Daiichi Sankyo Company, […]
Personalis, Inc. to Present at EACR Liquid Biopsies Virtual Event
18/11/2020 — MENLO PARK, Calif. — (BUSINESS WIRE) Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced that the company will participate in […]
Aptorum Group Launches Infectious Disease Liquid Biopsy Subsidiary Start-up and Exclusively In-licensed from Singapore based Accelerate Technologies To Co-Develop Molecular Based Rapid Pathogen Diagnostics Technology To Track Pathogenic Genome
29/09/2020 — NEW YORK, LONDON, & PARIS — (BUSINESS WIRE) Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focused on […]
Personalis, Inc. Launches NeXT Liquid Biopsy™, A High-Performance, Exome-Wide Liquid Biopsy Platform
Personalis, Inc. Launches NeXT Liquid Biopsy™, A High-Performance, Exome-Wide Liquid Biopsy Platform 03/08/2020 — MENLO PARK, Calif. — (BUSINESS WIRE) Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for […]
Personalis to Participate in European Association for Cancer Research (EACR) 2020 Virtual Congress
18/06/2020 — MENLO PARK, Calif. — (BUSINESS WIRE) Personalis, Inc., (Nasdaq: PSNL) a leader in advanced genomics for cancer, today announced the company’s participation in the European Association for Cancer […]
Asuragen to Present at 2020 European Society of Human Genetics (ESHG) Virtual Conference
Corporate satellite presentation and scientific posters highlight new AmplideX® testing kits 02/06/2020 — AUSTIN, Texas — (BUSINESS WIRE) Asuragen, Inc., a molecular diagnostics company delivering easy-to-use products for complex testing […]
Indivumed, Personalis Partner to Enhance Genomic Sequencing Capabilities
Collaboration to Advance Cancer Genomics Insights to Enable Novel Discoveries 21/04/2020 — HAMBURG, Germany & MENLO PARK, Calif. — (BUSINESS WIRE) Indivumed GmbH (“Indivumed”) and Personalis, Inc. (Nasdaq: PSNL) today […]
Aptorum Group Announces Significant Progress of Repurposed Drug Candidate, SACT-1 for Neuroblastoma Targeting IND Submission in H2 2020
10/02/2020 — NEW YORK — (BUSINESS WIRE) Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, […]
MEVION S250i Selected by Jinshazhou Hospital to Equip New Proton Therapy Center in Guangzhou, China
16/01/2020 — LITTLETON, Mass. — (BUSINESS WIRE) Mevion Medical Systems is pleased to announce it has signed an agreement for the sale of a MEVION S250i Proton Therapy System® with […]
Personalis, Inc. to Present at ESMO Immuno-Oncology Congress 2019
11/12/2019 — MENLO PARK, Calif. — (BUSINESS WIRE) Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will participate in the ESMO Immuno-Oncology […]